Sign up USA
Proactive Investors - Run By Investors For Investors

Theralase Technologies shares rocket on TLD-1433 clinical trial findings

The candidate is a light activated photo dynamic compound (PDC)
Theralase Technologies shares rocket on TLD-1433 clinical trial findings
Pictured - cancer cells

Shares in Theralase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) rocketed 25% in  Toronto as it unveiled very positive clinical trial news on its lead cancer compound TLD-1433.

The candidate is a light activated photo dynamic compound (PDC), which the firm is developing, and the trial is the first part of a Phase Ib clinical study for patients with non-muscle invasive bladder cancer (NMIBC).

First three patients...

After 90 days, the first three patients (which have remained drug resistant after the standard first line treatments) the exploratory efficacy endpoint was reached, using the maximum recommended starting dose.

"The company is ecstatic that after decades of hard work the company, in the first 3 patients treated, at the 90 day cystoscopy follow-up, at a MRSD (0.35 mg/cm2) of TLD-1433, that the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and now exploratory endpoint of efficacy have been achieved," said Roger Dumoulin-White, Theralase's president and chief executive.

"I wish to thank the entire Theralase board and employees, the clinical and scientific team and the Medical and Scientific Advisory Board, who have provided their knowledge, experience and worked tirelessly to make this day a reality."

No recurrence of lesions...

Theralase noted that the first three patients demonstrated no recurrence of NMIBC lesions at the 90 day cystoscopy analysis.

One patient presented with some reddened areas of the bladder wall, which will be biopsied at a future surgical date, while further clinical analysis will be conducted on the patients according to the approved clinical protocol.

Now, a further six patients for the second part of the study, are currently being enrolled, to be treated at a therapeutic dose of the PDC (0.70 mg/cm2) for NMIBC, using its novel PDT technology.

Shares added 25% to C$0.45 each.


View full TLT profile View Profile

Theralase Technologies Inc. Timeline

Related Articles

Empty meeting room
March 06 2018
The company's eponymous flagship product is not the only remote meetings enabler out there, but judging by the company's rapid growth, it is one of the best
November 13 2017
In the quarter, the power and electromechanical segment contributed revenues of $16.7 million,
Flow chart of the Hazer Process
March 21 2018
The Hazer Process could disrupt the $100 billion hydrogen production market.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use